Browse TDGF1

Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor Secreted Note=Released from the cell membrane by GPI cleavage.
Domain PF09443 Cripto_Frl-1_Cryptic (CFC)
Function

GPI-anchored cell membrane protein involved in Nodal signaling. Cell-associated TDGF1 acts as a Nodal coreceptor in cis. Shedding of TDGF1 by TMEM8A modulates Nodal signaling by allowing soluble TDGF1 to act as a Nodal coreceptor on other cells (PubMed:27881714). Could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm (PubMed:11909953).

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0000578 embryonic axis specification
GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0001763 morphogenesis of a branching structure
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0003002 regionalization
GO:0007350 blastoderm segmentation
GO:0007351 tripartite regional subdivision
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0008595 anterior/posterior axis specification, embryo
GO:0009798 axis specification
GO:0009880 embryonic pattern specification
GO:0009948 anterior/posterior axis specification
GO:0009952 anterior/posterior pattern specification
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0018105 peptidyl-serine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018212 peptidyl-tyrosine modification
GO:0019827 stem cell population maintenance
GO:0030335 positive regulation of cell migration
GO:0030879 mammary gland development
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035019 somatic stem cell population maintenance
GO:0035282 segmentation
GO:0035728 response to hepatocyte growth factor
GO:0035729 cellular response to hepatocyte growth factor stimulus
GO:0040017 positive regulation of locomotion
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045860 positive regulation of protein kinase activity
GO:0048514 blood vessel morphogenesis
GO:0048732 gland development
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0051272 positive regulation of cellular component movement
GO:0070741 response to interleukin-6
GO:0070849 response to epidermal growth factor
GO:0071346 cellular response to interferon-gamma
GO:0071354 cellular response to interleukin-6
GO:0071356 cellular response to tumor necrosis factor
GO:0071364 cellular response to epidermal growth factor stimulus
GO:0071774 response to fibroblast growth factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0098727 maintenance of cell number
GO:2000147 positive regulation of cell motility
Molecular Function GO:0008083 growth factor activity
Cellular Component GO:0016324 apical plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031225 anchored component of membrane
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-1433617: Regulation of signaling by NODAL
R-HSA-1181150: Signaling by NODAL
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TDGF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TDGF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TDGF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0070.991
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2350.808
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2980.788
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1330.851
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.350.809
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6840.662
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5410.273
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5410.447
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8140.00182
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TDGF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TDGF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TDGF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TDGF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TDGF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TDGF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TDGF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTDGF1
Nameteratocarcinoma-derived growth factor 1
Aliases Cripto-1; CRGF; cripto-1 growth factor; epidermal growth factor-like cripto protein CR1
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TDGF1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.